Nonwovens Industry
Welcome to Nonwovens Industry
FacebookRSSTwitterLinkedIn
Print RSS Feed

Biomedical Structures Expands Textile Engineering Capabilities



Published September 13, 2010
Related Searches: fiber

Biomedical Structures, a provider of biomedical textiles for medical devices and other advanced clinical applications has expanded its textile engineering capabilities with a new purpose-built cleanroom for high-density weaving and advanced braiding infrastructure for polymer and wire materials. BMS will support this growth by complementing its engineering expertise with new hires to the company’s technical workforce at its manufacturing facilities.


BMS’ newest cleanroom supports high-density weaving and knitting for biomedical textile production, and houses state-of-the-art warping and twisting equipment for an increased range of very fine and precise solutions for orthopedic, cardiovascular, and general surgery device applications.The facility addition is purpose-built for handling finer PET fibers, DSM Dyneema Purity and other mono- and multifilament fibers, especially those of lower denier. BMS recently teamed up with fiber manufacturer DSM Dyneema as a proven specialist in processing Dyneema Purity and Dyneema Purity BLUE, the first ever 100% colored implantable grade Ultra High Molecular Weight Polyethylene (UHMWPE) fiber.


Additionally, BMS has expanded its braiding capabilities with multiple new 16-carrier braiding machines, as well as a best-in-class 48-carrier machine for improved production capacity of polymer and wire braiding.In support of this expansion, the company has increased its manufacturing workforce with additional textile technicians, and plans to supplement current employee growth with more sales engineering and project management expertise in the near future.


“BMS has consistently worked to remain at the cutting edge of medical device product development,” said BMS president John Gray.“Our textile solutions are helping orthopedic and cardiovascular device manufacturers bring the next generation of more lifelike, high performance implantables and instruments to market.These expanded capabilities for more advanced engineering and production of our biomaterials will allow us to further innovate and deliver at the level our customers have come to expect.”